News
Important Only
U.S. Energy Corp. Reaches Final Investment Decision To Build Big Sky Carbon Hub Facility Targets Commercial Operations In Q1 2027
March 18 (Reuters) - US Energy Corp USEG.O:U.S. ENERGY CORP. REACHES FINAL INVESTMENT DECISION TO BUILD BIG SKY CARBON HUB FACILITY; TARGETS COMMERCIAL OPERATIONS IN Q1 2027Reuters
Wed, Mar 18
Arvinas Announces Positive Phase 1 Data For Arv-102 Showing Greater Than 50% Lrrk2 Degradation In The Csf Of Patients With Parkinson’S Disease Treated For 28 Days
March 18 (Reuters) - Arvinas Inc ARVN.O:ARVINAS ANNOUNCES POSITIVE PHASE 1 DATA FOR ARV-102 SHOWING GREATER THAN 50% LRRK2 DEGRADATION IN THE CSF OF PATIENTS WITH PARKINSON’S DISEASE TREATED FOR 28 DAYSARVINAS INC - NO SERIOUS ADVERSE EVENTS, DISCONTINUATIONS, OR DEATHS REPORTED WITH ARV-102ARVINAS ...Reuters
Wed, Mar 18
WeShop Announces Strategic Partnership With Caa Executive Search To Lead The Buildout Of Its U.S. Leadership Team
March 18 (Reuters) - Hot Rocks Investments PLC HRIP.ASE:WESHOP ANNOUNCES STRATEGIC PARTNERSHIP WITH CAA EXECUTIVE SEARCH TO LEAD THE BUILDOUT OF ITS U.S. LEADERSHIP TEAMReuters
Wed, Mar 18
Goodfood Announces Departure Of Its Chief Financial Officer And Expanded Role For VP Of Finance
March 18 (Reuters) - Goodfood Market Corp FOOD.TO:GOODFOOD ANNOUNCES DEPARTURE OF ITS CHIEF FINANCIAL OFFICER AND EXPANDED ROLE FOR VP OF FINANCEGOODFOOD MARKET CORP - ROSLANE AOUAMEUR TO DEPART AS CFO EFFECTIVE APRIL 22, 2026Reuters
Wed, Mar 18
Blue Moon Consolidates Apex Germanium And Gallium District With Acquisition Of Gage Properties From Liberty Gold
March 18 (Reuters) - Blue Moon Metals Inc MOON.V:BLUE MOON CONSOLIDATES APEX GERMANIUM AND GALLIUM DISTRICT WITH ACQUISITION OF GAGE PROPERTIES FROM LIBERTY GOLDBLUE MOON METALS INC - ACQUISITION CONSIDERATION IS 420,935 SHARES AND 2.0% NET SMELTER RETURN ROYALTYBLUE MOON METALS INC - BUYS 100% OF G...Reuters
Wed, Mar 18
SailPoint Announces Fiscal Fourth Quarter And Full Year 2026 Results
March 18 (Reuters) - Sailpoint Inc SAIL.O:SAILPOINT ANNOUNCES FISCAL FOURTH QUARTER AND FULL YEAR 2026 RESULTSSAILPOINT INC: FY26 TOTAL REVENUE $1.071 BILLIONSAILPOINT INC: FY26 TOTAL ARR $1.125 BILLIONSAILPOINT INC: Q4 TOTAL ARR WAS $1.125 BILLIONSAILPOINT INC: Q4 TOTAL REVENUE $295 MILLIONSAILPOIN...Reuters
Wed, Mar 18
Perfect Announces Receipt Of Preliminary Non-Binding “Going Private” Proposal
March 18 (Reuters) - Perfect Corp SZ9.F:PERFECT ANNOUNCES RECEIPT OF PRELIMINARY NON-BINDING “GOING PRIVATE” PROPOSALPERFECT CORP - RECEIVES PRELIMINARY NON-BINDING GOING PRIVATE PROPOSAL FOR $1.95 PER SHARE IN CASHPERFECT CORP - BOARD TO ESTABLISH SPECIAL COMMITTEE TO EVALUATE PROPOSALPERFECT CORP:...Reuters
Wed, Mar 18
Liberty Gold Announces The Sale Of The Gage Project
March 18 (Reuters) - Liberty Gold Corp LGD.TO:LIBERTY GOLD ANNOUNCES THE SALE OF THE GAGE PROJECTLIBERTY GOLD CORP - TO DIVEST GAGE PROJECT FOR 420,935 BLUE MOON SHARES AND 2.0% NSR ROYALTYLIBERTY GOLD CORP - TO RECEIVE ABOUT $2 MILLION VIA 420,935 BLUE MOON SHARESReuters
Wed, Mar 18
Macy's Sees FY Adj EPS $1.90 To $2.10
March 18 (Reuters) - Macy's Inc M.N:MACY'S Q4 ADJUSTED EPS $1.67 VERSUS. IBES ESTIMATE $1.53MACY'S OUTLOOK FY SALES $21.4 BILLION TO $21.65 BILLION VERSUS. IBES ESTIMATE $21.85 BILLIONMACY'S Q4 COMP SALES UP 1.8%MACY'S OUTLOOK FY ADJUSTED EPS $1.90 TO $2.10 VERSUS. IBES ESTIMATE ...Reuters
Wed, Mar 18
A&W Food Services Of Canada Inc. Announces Commencement Of Normal Course Issuer Bid
March 18 (Reuters) - A&W Food Services of Canada Inc AW.TO:A&W FOOD SERVICES OF CANADA INC. ANNOUNCES COMMENCEMENT OF NORMAL COURSE ISSUER BIDA&W FOOD SERVICES OF CANADA INC - RECEIVES TSX APPROVAL FOR NORMAL COURSE ISSUER BIDReuters
Wed, Mar 18
Kalvista Pharmaceuticals To Report Eight Months Fiscal Year 2025 Financial Results And Provide Corporate Update On March 25, 2026
March 18 (Reuters) - Kalvista Pharmaceuticals Inc KALV.O:KALVISTA PHARMACEUTICALS TO REPORT EIGHT MONTHS FISCAL YEAR 2025 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON MARCH 25, 2026Reuters
Wed, Mar 18
Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis
March 18 (Reuters) - Aclaris Therapeutics Inc ACRS.O:ACLARIS THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 TRIAL OF BOSAKITUG (ATI-045) IN ATOPIC DERMATITISACLARIS THERAPEUTICS INC - TOP LINE RESULTS FROM PHASE 2 TRIAL EXPECTED IN Q4 2026Reuters
Wed, Mar 18
